Michael DiFiore is a managing director on Wall Street’s consistently-#1-ranked biopharma research team covering Major Pharma, Large Cap Biotech, Specialty Pharma, and SMID biotech.
In 2025 and 2024, he ranked #6 and #5, respectively, on the Extel (formerly Institutional Investor) All-America Research Team as a runner-up in the specialty pharma sector.
Mr. DiFiore has over a decade of experience covering a wide range of biopharma companies, having joined Evercore in late 2015.
Prior to Wall Street, Mr. DiFiore spent 13 years in the biopharma industry, working in various commercial and medical affairs capacities.
In addition to earning his MBA in finance from NYU’s Stern School of Business, he also earned his Pharm.D. and B.S. degrees from the Ernest Mario School of Pharmacy at Rutgers University.
